Association of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer.
dc.contributor.author | Nyrop, KA | |
dc.contributor.author | Page, A | |
dc.contributor.author | Deal, AM | |
dc.contributor.author | Wagoner, C | |
dc.contributor.author | Kelly, EA | |
dc.contributor.author | Kimmick, Gretchen G | |
dc.contributor.author | Copeland, Anureet | |
dc.contributor.author | Speca, JoEllen | |
dc.contributor.author | Wood, William A | |
dc.contributor.author | Muss, HB | |
dc.date.accessioned | 2024-01-01T23:26:48Z | |
dc.date.available | 2024-01-01T23:26:48Z | |
dc.date.issued | 2023-12 | |
dc.description.abstract | BackgroundIn the field of exercise oncology, there is a need to quantify the potential benefits of moderate, self-directed physical activity during active treatment. In a pooled analysis of three identical single-arm intervention studies, we investigate the association of activity tracker steps with patient-reported toxicities during chemotherapy.MethodsWomen with early breast cancer who were enrolled in the intervention studies reported their symptom severity every 2-3 weeks throughout chemotherapy, and daily steps were documented through a Fitbit activity tracker. Relative risks (RR) and 95% confidence intervals (CI) were calculated using Poisson regression models with robust variance. For outcomes significant in unadjusted models, adjusted RRs were calculated controlling for race, age, and education level. Tracker step cut point (high step, low step) was determined by the means. Cumulative incidence functions of moderate, severe, and very severe (MSVS) symptoms were estimated using the Kaplan-Meier method and compared using a Cox proportional hazard model.ResultsIn a sample of 283 women, mean age was 56 years and 76% were White. Mean tracker-documented steps/week were 29,625, with 55% walking below the mean (low step) and 45% above (high step). In multivariable analysis, high step patients had lower risk for fatigue [RR 0.83 (0.70, 0.99)] (p = 0.04), anxiety [RR 0.59 (0.42, 0.84)] (p = 0.003), nausea [RR 0.66 (0.46, 0.96)] (p = 0.03), depression [RR 0.59 (0.37, 0.03)] (p = 0.02), and ≥ 6 MSVS symptoms [RR 0.73 (0.54, 1.00)] (p = 0.05) and had 36% lower risk for dose reductions [RR 0.64 (95% CI 0.43, 0.97)] (p = 0.03).ConclusionSelf-directed walking at a rate of at least 30,000 steps/week may moderate the severity of treatment side effects during chemotherapy for early breast cancer.Trial numbersNCT02167932, NCT02328313, NCT03761706. | |
dc.identifier | 10.1007/s00520-023-08275-4 | |
dc.identifier.issn | 0941-4355 | |
dc.identifier.issn | 1433-7339 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.relation.ispartof | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | |
dc.relation.isversionof | 10.1007/s00520-023-08275-4 | |
dc.rights.uri | ||
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Exercise | |
dc.subject | Walking | |
dc.subject | Anxiety | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Drug-Related Side Effects and Adverse Reactions | |
dc.title | Association of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer. | |
dc.type | Journal article | |
pubs.begin-page | 68 | |
pubs.issue | 1 | |
pubs.organisational-group | Duke | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Medicine, Medical Oncology | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.publication-status | Published | |
pubs.volume | 32 |
Files
Original bundle
- Name:
- SuppCareCancer Nyrop2024_selfdirected walking&tox in EBC.pdf
- Size:
- 1.1 MB
- Format:
- Adobe Portable Document Format